Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis.
Acute Disease
Antiemetics
/ adverse effects
Child
Child, Preschool
Dexamethasone
/ therapeutic use
Diarrhea
/ chemically induced
Dimenhydrinate
/ therapeutic use
Domperidone
/ therapeutic use
Fluid Therapy
/ statistics & numerical data
Gastroenteritis
/ complications
Granisetron
/ therapeutic use
Hospitalization
Humans
Infant
Metoclopramide
/ therapeutic use
Network Meta-Analysis
Ondansetron
/ therapeutic use
Randomized Controlled Trials as Topic
Regression Analysis
Vomiting
/ complications
Journal
Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
accepted:
22
01
2020
pubmed:
7
3
2020
medline:
27
6
2020
entrez:
6
3
2020
Statut:
ppublish
Résumé
Several antiemetics have been used in children with acute gastroenteritis. However, there is still controversy over their use. To determine the effectiveness and safety of antiemetics for controlling vomiting in children with acute gastroenteritis. Medline, Embase, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, Latin America and the Caribbean Literature on Health Sciences, and gray literature, until December 2018. We selected randomized clinical trials comparing metoclopramide, ondansetron, domperidone, dexamethasone, dimenhydrinate, and granisetron. Two reviewers independently screened abstracts and full texts, extracted the data, and assessed the risk of bias. We performed pairwise and network meta-analysis using the random-effects model. Twenty-four studies were included (3482 children). Ondansetron revealed the largest effect in comparison to placebo for cessation of vomiting (odds ratio = 0.28 [95% credible interval = 0.16 to 0.46]; quality of evidence: high) and for hospitalization (odds ratio = 2.93 [95% credible interval = 1.69 to 6.18]; quality of evidence: moderate). Ondansetron was the only intervention that reduced the need for intravenous rehydration and the number of vomiting episodes. When considering side effects, dimenhydrinate was the only intervention that was worse than placebo. Most treatment comparisons had low- or very low-quality evidence, because of risk of biases and imprecise estimates. Ondansetron is the only intervention that revealed an effect on the cessation of vomiting, on preventing hospitalizations, and in reducing the need for intravenous rehydration. Ondansetron was also considered a safe intervention.
Identifiants
pubmed: 32132152
pii: peds.2019-3260
doi: 10.1542/peds.2019-3260
pii:
doi:
Substances chimiques
Antiemetics
0
Ondansetron
4AF302ESOS
Domperidone
5587267Z69
Dexamethasone
7S5I7G3JQL
Dimenhydrinate
JB937PER5C
Metoclopramide
L4YEB44I46
Granisetron
WZG3J2MCOL
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 by the American Academy of Pediatrics.
Déclaration de conflit d'intérêts
POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.